miR‑133b induces chemoresistance of osteosarcoma cells to cisplatin treatment by promoting cell death, migration and invasion Retraction in /10.3892/ol.2024.14308

Zou,Yonggen; Yang,Jiexiang; Wu,Jian; Luo,Cheng; Huang,Yuanshuai

doi:10.3892/ol.2017.7432

miR‑133b induces chemoresistance of osteosarcoma cells to cisplatin treatment by promoting cell death, migration and invasion

Retraction in: /10.3892/ol.2024.14308

Authors:
- Yonggen Zou
- Jiexiang Yang
- Jian Wu
- Cheng Luo
- Yuanshuai Huang
View Affiliations

Affiliations: Department of Orthopedics, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China, Department of Transfusion, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China
Published online on: November 16, 2017 https://doi.org/10.3892/ol.2017.7432
Pages: 1097-1102
Copyright: © Zou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As an important chemotherapeutic agent for the treatment of osteosarcoma, the effectiveness of cisplatin is considered to be due to its unique properties, which allow it to penetrate the cell membrane and form various DNA‑platinum adducts, resulting in genetic alterations or DNA damage. However, chemoresistance to cisplatin remains a major challenge for its use and chemotherapeutic effects. In the present study, an isogenic model of a cisplatin resistant osteosarcoma cell line, MG63‑DDP, was generated from the original MG63 cell line. The expression level of microRNA (miR)‑133b in the MG63‑DDP cisplatin‑resistant osteosarcoma cell line was analyzed by reverse transcription‑quantitative polymerase chain reaction (PCR). Cisplatin‑DNA adduct formation, cell death (carboxyfluorescein succinimidyl ester/propidium iodide staining) and clonogenic survival assays (crystal violet staining) were performed, comparing various cell types. The effect of miR‑133b on migration (scratch wound assay) and invasion (Transwell assay) was also evaluated. Characterization studies have previously revealed an increased level of miR‑133b in MG63‑DDP cells compared with normal MG63 cells. Upregulation of miR‑133b was associated with the accumulation of cisplatin‑DNA adducts and an increase in cisplatin‑induced cell death. Furthermore, increased miR‑133b expression levels enhanced the migration and invasion of MG63 cells under cisplatin stress. Concordantly, in MG63‑DDP cells the neutralization of miR‑133b demonstrated opposite effects, as compared with the upregulation of miR‑133b. To the best of our knowledge, the present study demonstrated for the first time that cisplatin‑resistant MG63 cells exhibit an increased level of miR‑133b expression. The endogenous expression level of miR‑133b is sufficient for inducing cisplatin resistance, which suggests that miR‑133b may be a biomarker for cisplatin resistance in osteosarcoma.

View Figures

View References

1	Fink-Puches R, Zenahlik P, Bäck B, Smolle J, Kerl H and Cerroni L: Primary cutaneous lymphomas: Applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood. 99:800–805. 2002. View Article : Google Scholar : PubMed/NCBI
2	Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, et al: Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 21:2011–2018. 2003. View Article : Google Scholar : PubMed/NCBI
3	Bacci G, Briccoli A, Rocca M, Ferrari S, Donati D, Longhi A, Bertoni F, Bacchini P, Giacomini S, Forni C, et al: Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: Recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 14:1126–1134. 2003. View Article : Google Scholar : PubMed/NCBI
4	Thomas M, Lieberman J and Lal A: Desperately seeking microRNA targets. Nat Struct Mol Biol. 17:1169–1174. 2010. View Article : Google Scholar : PubMed/NCBI
5	Sassen S, Miska EA and Caldas C: MicroRNA: Implications for cancer. Virchows Arch. 452:1–10. 2008. View Article : Google Scholar : PubMed/NCBI
6	Schetter AJ and Harris CC: Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol. 38:734–742. 2011. View Article : Google Scholar : PubMed/NCBI
7	Schetter AJ, Okayama H and Harris CC: The role of microRNAs in colorectal cancer. Cancer J. 18:244–252. 2012. View Article : Google Scholar : PubMed/NCBI
8	Hayes CN and Chayama K: MicroRNAs as biomarkers for liver disease and hepatocellular carcinoma. Int J Mol Sci. 17:2802016. View Article : Google Scholar : PubMed/NCBI
9	Vanas V, Haigl B, Stockhammer V and Sutterlüty-Fall H: MicroRNA-21 increases proliferation and cisplatin sensitivity of osteosarcoma-derived cells. PLoS One. 11:e01610232016. View Article : Google Scholar : PubMed/NCBI
10	Yuan J, Chen L, Chen X, Sun W and Zhou X: Identification of serum microRNA-21 as a biomarker for chemosensitivity and prognosis in human osteosarcoma. J Int Med Res. 40:2090–2097. 2012. View Article : Google Scholar : PubMed/NCBI
11	Yan K, Gao J, Yang T, Ma Q, Qiu X, Fan Q and Ma B: MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma both in vitro and in vivo. PLoS One. 7:e337782012. View Article : Google Scholar : PubMed/NCBI
12	He C, Xiong J, Xu X, Lu W, Liu L, Xiao D and Wang D: Functional elucidation of miR-34 in osteosarcoma cells and primary tumor samples. Biochem Biophys Res Commun. 388:35–40. 2009. View Article : Google Scholar : PubMed/NCBI
13	Duan Z, Choy E, Harmon D, Liu X, Susa M, Mankin H and Hornicek F: MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther. 10:1337–1345. 2011. View Article : Google Scholar : PubMed/NCBI
14	Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, Blay JY and Alberti L: Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer. 129:680–690. 2011. View Article : Google Scholar : PubMed/NCBI
15	Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, et al: Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene. 28:4065–4074. 2009. View Article : Google Scholar : PubMed/NCBI
16	Haas JD, Nistala K, Petermann F, Saran N, Chennupati V, Schmitz S, Korn T, Wedderburn LR, Förster R, Krueger A and Prinz I: Expression of miRNAs iR-133b and miR-206 in the II17a/f locus is co-regulated with IL-17 production in αβ and γδ T cells. PLoS One. 6:e201712011. View Article : Google Scholar : PubMed/NCBI
17	Novello C, Pazzaglia L, Cingolani C, Conti A, Quattrini I, Manara MC, Tognon M, Picci P and Benassi MS: miRNA expression profile in human osteosarcoma: Role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol. 42:667–675. 2013. View Article : Google Scholar : PubMed/NCBI
18	Zhao H, Li M, Li L, Yang X, Lan G and Zhang Y: miR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration, and invasion and promotes apoptosis. PLoS One. 8:e835712013. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
21	Shen DW, Pouliot LM, Hall MD and Gottesman MM: Cisplatin resistance: A cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 64:706–721. 2012. View Article : Google Scholar : PubMed/NCBI
22	Grossi V, Peserico A, Tezil T and Simone C: p38α MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance. World J Gastroenterol. 20:9744–9758. 2014. View Article : Google Scholar : PubMed/NCBI
23	Wang G, Rong J, Zhou Z and Duo J: Novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2 and Bax in osteosarcoma cells. Mol Biol (Mosk). 44:1010–1017. 2010. View Article : Google Scholar : PubMed/NCBI
24	Pasello M, Michelacci F, Scionti I, Hattinger CM, Zuntini M, Caccuri AM, Scotlandi K, Picci P and Serra M: Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res. 68:6661–6668. 2008. View Article : Google Scholar : PubMed/NCBI
25	Huang J, Liu K, Yu Y, Xie M, Kang R, Vernon P, Cao L, Tang D and Ni J: Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma. Autophagy. 8:275–277. 2012. View Article : Google Scholar : PubMed/NCBI
26	Dai H, Huang Y, Li Y, Meng G, Wang Y and Guo QN: TSSC3 overexpression associates with growth inhibition, apoptosis induction and enhances chemotherapeutic effects in human osteosarcoma. Carcinogenesis. 33:30–40. 2012. View Article : Google Scholar : PubMed/NCBI
27	Xu X, Wells A, Padilla MT, Kato K, Kim KC and Lin Y: Asignaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance. Carcinogenesis. 35:2457–2466. 2014. View Article : Google Scholar : PubMed/NCBI
28	Jiang L, Tao C, He A and He X: Overexpression of miR-126 sensitizes osteosarcoma cells to apoptosis induced by epigallocatechin-3-gallate. World J Surg Oncol. 12:3832014. View Article : Google Scholar : PubMed/NCBI
29	Zhou Y, Huang Z, Wu S, Zang X, Liu M and Shi J: miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulatin TWIST. J Exp Clin Cancer Res. 33:122014. View Article : Google Scholar : PubMed/NCBI
30	Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, Ji Z, Zhao J, Zhao H, Guo M, et al: MicroRNA-221 induces cell survival and cisplatin resistance through P13 K/Akt pathway in human osteosarcoma. PLoS One. 8:e539062013. View Article : Google Scholar : PubMed/NCBI
31	Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL and Wang DZ: The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 38:228–233. 2006. View Article : Google Scholar : PubMed/NCBI
32	Chen X, Wu B, Xu Z, Li S, Tan S, Liu X and Wang K: Downregulation of miR-133b predict progression and poor prognosis in patients with urothelial carcinoma of bladder. Cancer Med. 5:1856–1862. 2016. View Article : Google Scholar : PubMed/NCBI
33	Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin C and Zhang W: microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep. 27:1967–1975. 2012.PubMed/NCBI